Sanofi Goes All The Way In mRNA With Translate Bio Buy
French Giant Paying $3.2bn
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.